Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVAX stock price vs SNV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SNV's multiple
Needs SNV P/E.
Implied fair value · at NVAX's multiple
Needs NVAX P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NVAX FY 2025 (ended Dec 31, 2025) · SNV FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
NOVAVAX INC · implied price per share
Bear
$24.71
Base
$29.07
Bull
$33.44
SYNOVUS FINANCIAL CORP · implied price per share
Bear
$159.26
Base
$187.36
Bull
$215.47
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.33x
Net debt / EBITDA
Leverage against operating earnings
-1.55x
-0.80x
Cash and equivalents
Liquid reserves on the balance sheet
$735.08M
$4.39B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
NVAX vs MRNA
BioNTech SE
NVAX vs BNTX
Emergent BioSolutions Inc.
NVAX vs EBS
ASTRAZENECA PLC
NVAX vs AZN
GSK plc
NVAX vs GSK
REGIONS FINANCIAL CORP
NVAX vs RF
FIFTH THIRD BANCORP
NVAX vs FITB
HUNTINGTON BANCSHARES INC /MD/
NVAX vs HBAN
COMERICA INC /NEW/
NVAX vs CMA
M&T BANK CORP
NVAX vs MTB
$395.00K
$1.74B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
